2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
11
Neoplasms
3
Lung Neoplasms
2
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
1
Non-Small Cell Lung Cancer Metastatic
1
Hematologic Neoplasms
1
Gastrointestinal Neoplasms
1
Deafness, Autosomal Recessive 39
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma
1
Interventions
Trastuzumab
625
Paclitaxel
576
Cyclophosphamide
555
Docetaxel
484
Capecitabine
401
Letrozole
376
Fulvestrant
326
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
184
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
138
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
tepotinib
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled